Interview with Dr Attila Nemeth on schizophrenia in practice

Interview with Dr Attila Nemeth, Hungary on talking to patients with schizophrenia and other issues about the condition.

Q. When you first tell a patient they have schizophrenia, do you tell them this is a lifelong condition?

A. Usually we tell patients that schizophrenia is a lifelong condition but that 20% of patients may only experience a single psychotic episode.

Q. Having made a diagnosis of schizophrenia – do you tell patients at that point how long they are likely to need to be on medication?

A. It depends on the condition of the patients. We believe in the early pharmacological treatment of all patients with schizophrenia but we monitor patients. If they are symptom-free for 3 years or more, we would consider stopping therapy but would continue with regular follow-ups.  A maximum of 25% of patients with schizophrenia may be medication-free after 3 years.

Q. What factors have a large contribution to the quality of life of a patient with schizophrenia?

A. Live-in family support and having a place of work, rather than being in a hospital or an institution, definitely contribute positively to a patient’s quality of life.

Q. Do you think of schizophrenia as a neurodevelopmental disorder or as a neurodegenerative disease?

A. Schizophrenia has a complex aetiology; genetics, recreational drug use, family circumstances and psychological factors all contribute towards the disease. In my opinion, genetic and biological factors are likely to be more important contributory factors than psychological factors.

Q. What proportion of patients with schizophrenia have the potential to achieve improvements in relationships?

A. 80-90% of those patients with a good prognosis due to effective therapy are likely to improve their relationships. Of course, if patients don’t comply with their medication, this doesn’t help their prognosis.

The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente agli Operatori Sanitari (medici e farmacisti). I contenuti di questo sito sono prodotti da un team di Operatori Sanitari il cui obiettivo è presentare le ultime novità in ambito psichiatrico e neurologico, attraverso interviste, registrazioni audio/video di seminari con opinion leader, report e sintesi di congressi sia internazionali che nazionali. Per poter accedere al sito è quindi necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Operatore Sanitario.
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country